Resmed (NYSE:RMD) has completed its acquisition of Noctrix Health, a wearable-therapeutics company for chronic neurological disorders. The deal adds Noctrix’s Nidra TOMAC Therapy, an FDA De Novo classified, non-invasive, non-pharmacologic treatment for moderate-to-severe Restless Legs Syndrome (RLS), to Resmed’s clinical sleep health portfolio.
Noctrix becomes a wholly owned Resmed subsidiary, supporting Resmed’s 2030 strategy by expanding into RLS, the third most prevalent sleep disorder, with a clinically validated therapy backed by 10 peer-reviewed publications and inclusion in AASM clinical practice guidelines.
Loading...
Loading translation...
Positive
Completed acquisition of Noctrix Health expands RLS treatment portfolio
Adds FDA De Novo classified, non-invasive TOMAC therapy for moderate-to-severe RLS
Access to therapy included in AASM RLS clinical practice guidelines
Noctrix therapy supported by 10 peer-reviewed clinical publications
Supports Resmed’s 2030 strategy in clinical sleep health and home care
Negative
None.
News Market Reaction – RMD
-1.94%
-1.94%Session close to close
In the Jun 2 session, RMD declined 1.94%, reflecting a mild negative market reaction.
This announcement expands Resmed’s clinical sleep health portfolio into Restless Legs Syndrome via N...
Analysis
This announcement expands Resmed’s clinical sleep health portfolio into Restless Legs Syndrome via Noctrix’s TOMAC therapy, an FDA De Novo classified, non-pharmacologic treatment supported by 10 peer-reviewed publications and inclusion in AASM guidelines. It follows earlier integration moves like the VirtuOx acquisition to deepen digital and home-based care. Investors may watch how quickly TOMAC is integrated into Resmed’s connected devices, adoption trends, and future earnings disclosures quantifying its contribution.
Key Figures
Peer-reviewed publications:10 publications
1 metrics
Peer-reviewed publications10 publicationsClinical validation of TOMAC therapy for RLS
Acquisition of VirtuOx to expand at-home diagnostic and virtual care capabilities.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Prior acquisition news saw a very small negative move, suggesting historically muted price impact from such deals.
Recent Company History
Over recent quarters, Resmed has combined solid financial execution with strategic moves to broaden its sleep and respiratory ecosystem. The VirtuOx acquisition on May 1, 2025 extended its virtual diagnostic capabilities and operated as a wholly owned subsidiary. More recently, earnings and leadership updates showed continued revenue growth and margin expansion. Today’s Noctrix deal fits this pattern of bolt-on acquisitions aimed at expanding clinical sleep health offerings into adjacent indications like Restless Legs Syndrome.
Key Terms
fda de novo, restless legs syndrome, rls, tonic motor activation (tomac) therapy, +4 more
8 terms
fda de novoregulatory
"Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment"
The FDA De Novo pathway is a U.S. regulatory process that grants market authorization for novel medical devices that are low-to-moderate risk but don’t fit into any existing device category, creating a new device class and basic safety rules. For investors, De Novo clearance is like receiving official permission and a playbook to sell a new gadget: it can speed market entry and create a competitive edge, but it still involves review uncertainty, compliance costs, and ongoing oversight.
restless legs syndromemedical
"designed to address moderate-to-severe Restless Legs Syndrome (RLS)"
A nervous system disorder that causes an uncomfortable urge to move the legs, often described as crawling, tingling or aching sensations that worsen at rest and at night. For investors, it matters because the condition drives demand for medical treatments, devices and ongoing care; advances in therapies or regulatory decisions can affect the commercial prospects and revenue of companies developing drugs, diagnostics or sleep-related products. Think of it like a repeated nuisance that requires ongoing solutions rather than a one-time fix.
rlsmedical
"the treatment of Restless Legs Syndrome (RLS), the third most prevalent sleep disorder"
Restless Legs Syndrome (RLS) is a neurological condition that causes an uncontrollable urge to move the legs, often accompanied by uncomfortable sensations that worsen at rest or at night. For investors, RLS matters because it creates a defined patient population and medical need that drives demand for therapies, affects clinical trial design and outcomes, and influences the commercial potential and regulatory pathway for drugs or devices—think of it as a clear market signal for healthcare products.
tonic motor activation (tomac) therapymedical
"Noctrix’s Nidra® Tonic Motor Activation (TOMAC) Therapy is an FDA De Novo classified"
Tonic motor activation (ToMAC) therapy is a medical treatment that uses gentle, continuous electrical impulses to keep specific muscles or nerves active, helping restore steady muscle control and reduce involuntary loss of function. Think of it like a low-speed engine idle that keeps a car ready to move smoothly instead of stalling; for investors, its importance lies in potential clinical benefits, regulatory approval hurdles, adoption by clinicians, and reimbursement prospects that drive commercial value.
non-pharmacologicmedical
"non-invasive, non-pharmacologic treatment designed to reduce symptoms of moderate-to-severe RLS"
Non-pharmacologic describes treatments or interventions that do not use drugs or pharmaceuticals, such as medical devices, physical therapies, behavioral programs, surgical procedures, or lifestyle changes like diet and exercise. For investors, these options matter because they follow different regulatory pathways, cost structures and reimbursement rules than drugs, often implying different development timelines, risks and market opportunities — like choosing a tool or training instead of a pill.
american academy of sleep medicine (aasm)medical
"inclusion in the American Academy of Sleep Medicine (AASM) clinical practice guidelines"
AASM is the leading U.S. professional organization for sleep medicine that sets clinical standards, certifies specialists, and accredits sleep centers, similar to a referee and seal of approval for how sleep disorders are diagnosed and treated. Investors care because its guidelines and accreditations shape which tests, devices, and therapies gain clinical acceptance, insurance coverage, and wider adoption—affecting market size, reimbursement and product credibility.
clinical practice guidelinesmedical
"AASM clinical practice guidelines for the treatment of RLS"
Clinical practice guidelines are systematically developed recommendations that tell healthcare providers the best ways to diagnose, treat, or prevent medical conditions, based on a review of evidence and expert judgment. They matter to investors because guidelines shape how widely a drug, device, or service will be used and paid for — like a recipe doctors and hospitals follow that can expand or restrict a product’s market and revenue predictability.
wearable therapeuticsmedical
"a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders"
Wearable therapeutics are medical devices or technology you wear on your body that actively treat or manage a health condition—for example by delivering medication, electrical stimulation, or tailored therapy programs—while often collecting data about the wearer. Investors care because these products can create steady revenue streams, scale through software updates, and change healthcare costs and patient demand; their commercial value hinges on clinical proof, regulatory approval, and insurance coverage.
Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS).
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has completed its acquisition of Noctrix Health, Inc., a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders.
The acquisition expands Resmed’s clinical sleep health portfolio into an adjacent area of significant unmet need — the treatment of Restless Legs Syndrome (RLS), the third most prevalent sleep disorder.1,2 For Noctrix Health, joining Resmed brings an opportunity to scale its innovation, expand patient access, and accelerate impact for providers, patients and health systems.
Noctrix’s Nidra® Tonic Motor Activation (TOMAC) Therapy is an FDA De Novo classified, non-invasive, non-pharmacologic treatment designed to reduce symptoms of moderate-to-severe RLS and improve sleep quality in adults who have not found sufficient relief with drug therapy.3,4 For many patients, this therapy can deliver meaningful improvement in daily life and overall sleep health. 5
Noctrix has rapidly built a strong foundation of clinical validation for its breakthrough therapy, including 10 peer-reviewed publications and inclusion in the American Academy of Sleep Medicine (AASM) clinical practice guidelines for the treatment of RLS — notable achievements that reflect both scientific validation and growing clinical adoption.
“Our acquisition of Noctrix Health marks an important step forward in advancing our 2030 strategy and expanding our clinical sleep health portfolio,” said Mick Farrell, Chairman and CEO of Resmed. “We are excited to welcome the Noctrix team to Resmed and scale solutions that improve lives through better sleep and home health technologies.”
Resmed plans to integrate Noctrix’s technology into its portfolio of connected devices and digital health solutions to help expand access, improve care pathways and enhance patient outcomes over time.
“Since founding Noctrix, our mission has been to deliver innovative, non-pharmacologic solutions for people living with RLS who have limited treatment options,” said Shri Raghunathan, President and CEO of Noctrix Health. “Joining Resmed will help us advance that mission, enabling us to expand access to TOMAC therapy and reach more patients with a clinically validated solution that can help meaningfully improve sleep and quality of life.”
Completion of Acquisition
Resmed’s acquisition of Noctrix Health, Inc. was previously announced on April 30, 2026, during Resmed’s Q3 FY26 earnings call. Upon completion of the acquisition today, Noctrix became a wholly owned subsidiary within the Resmed group.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more at Resmed.com and follow @Resmed.
1McArdle N, et al. Prevalence of common sleep disorders in a middle-aged community sample. J Clin Sleep Med. 2022;18:1503–1514. (Identifies insomnia, obstructive sleep apnea, and RLS as among the most common sleep disorders). 2Winkelman JW, Wipper B. Restless Legs Syndrome: A Review. JAMA. 2026;335(8):703–714. (~8% of adults report RLS symptoms; associated with sleep disturbance and reduced quality of life). 3U.S. Food and Drug Administration. De Novo Classification Request: NTX100 Tonic Motor Activation System (DEN220059). 2023. (Device indicated to reduce symptoms of moderate-to-severe RLS and improve sleep quality in adults refractory to medications). 4Ryschon AM, et al. Cost-Effectiveness of Tonic Motor Activation Therapy for RLS. Neurology and Therapy. 2023. (Identifies TOMAC as a nonpharmacologic treatment for medication-refractory RLS). 5Winkelman JW, Wipper B. Restless Legs Syndrome: A Review. JAMA. 2026;335(8):703–714. (~8% of adults report RLS symptoms; associated with sleep disturbance and reduced quality of life).
FAQ
What did Resmed (RMD) announce about its acquisition of Noctrix Health on June 1, 2026?
Resmed announced it has completed the acquisition of Noctrix Health, which now operates as a wholly owned subsidiary. According to Resmed, this transaction expands its clinical sleep health portfolio into Restless Legs Syndrome with a clinically validated, non-pharmacologic wearable therapy.
How does the Noctrix Health acquisition expand Resmed (RMD) into Restless Legs Syndrome treatment?
The acquisition gives Resmed access to Noctrix’s Nidra TOMAC Therapy for moderate-to-severe Restless Legs Syndrome. According to Resmed, this FDA De Novo classified, non-pharmacologic therapy targets adults not adequately helped by drug treatments, broadening Resmed’s presence in clinical sleep health.
What is Nidra TOMAC Therapy added to Resmed’s (RMD) portfolio through Noctrix Health?
Nidra TOMAC Therapy is a non-invasive, non-pharmacologic treatment designed to reduce moderate-to-severe RLS symptoms. According to Resmed, the FDA De Novo classified therapy aims to improve sleep quality in adults and can meaningfully enhance daily life and overall sleep health.
How clinically validated is Noctrix Health’s TOMAC therapy now owned by Resmed (RMD)?
Noctrix’s TOMAC therapy has a foundation of clinical validation, including 10 peer-reviewed publications and guideline inclusion. According to Resmed, the therapy appears in American Academy of Sleep Medicine RLS clinical practice guidelines, indicating recognition within sleep medicine and growing clinical adoption.
How does the Noctrix Health acquisition support Resmed’s (RMD) 2030 strategy?
The acquisition is described as an important step in advancing Resmed’s 2030 strategy. According to Resmed, integrating Noctrix’s RLS technology into its connected devices and digital health solutions should expand access, improve care pathways, and enhance patient outcomes over time.
What does Noctrix Health gain by becoming a Resmed (RMD) subsidiary?
Noctrix gains the ability to scale its TOMAC therapy and broaden patient access through Resmed’s platform. According to Noctrix and Resmed, the combination is expected to expand reach to people with RLS who have limited non-pharmacologic treatment options.
When was the Resmed (RMD) acquisition of Noctrix Health first disclosed to investors?
The acquisition was first announced on April 30, 2026, during Resmed’s Q3 FY26 earnings call. According to Resmed, legal completion occurred on June 1, 2026, when Noctrix became a wholly owned subsidiary within the Resmed group.
